Scinai Immunotherapeutics Ltd ADR (SCNI) Stock Price, Quote & News

Company Profile

Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufac...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 8 930 2529

Fax: 972 8 930 2531

Website: www.scinai.com

Address:

Jerusalem BioPark, 2nd floor Hadassah Ein Kerem Campus, Jerusalem, Israel

focafoca99 May. 12 at 9:53 PM

$SCNI scheduled its annual shareholders meeting for June 16, 2026.

0 · Reply

CrumbEater May. 8 at 7:46 PM

$SCNI https://www.stocktitan.net/sec-filings/SCNI/6-k-scinai-immunotherapeutics-ltd-current-report-foreign-issuer-a6b6d38f512a.html

0 · Reply

focafoca99 May. 8 at 11:40 AM

$SCNI declares it completed the acquisition of Recipharm Israel and filed audited and pro forma financial statements of the new subsidiary.

0 · Reply

SuperGreenToday Apr. 30 at 8:45 PM

$SCNI

0 · Reply

Richard_Roma Apr. 29 at 1:37 PM

$SCNI of course another placement to dilute shateholders and provide a comfortable living to execs for non-performance.

0 · Reply

Bulltrader988 Apr. 28 at 6:55 PM

$SCNI From yesterdays filling: " ...Closing Date” means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i) the Purchasers’ obligations to pay the Subscription Amount and (ii) the Company’s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the first Trading Day following the date hereof if this Agreement is entered into before 4 p.m. Eastern time, or no later than the second Trading Day following the date hereof, if this Agreement is entered at or after 4 p.m. Eastern time...." 👃👀 https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319982642&type=HTML&symbol=SCNI&cdn=27e649d3764bf88cf25ce26b2bd729ff&companyName=Scinai+Immunotherapeutics+Ltd.&formType=6-K&formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&dateFiled=2026-04-27

0 · Reply

NewbieStar Apr. 28 at 2:13 AM

$SCNI just got in. Looking at exiting at $5

1 · Reply

Joby099 Apr. 27 at 9:24 PM

$SCNI

0 · Reply

Richard_Roma Apr. 27 at 8:40 PM

$SCNI are you not entertained? This flaming dumpster will probably be up for another placement soon, as execs need to maintain their higher standard of living.

0 · Reply

rbobby25 Apr. 27 at 3:28 PM

$SCNI - just jumped into this stock and bought 5000 shares to start. See how today/this week rolls. Looks promising for a bit of a lift off upwards.

1 · Reply

Why Is Scinai Immunotherapeutics Stock (SCNI) Up Today?

Fri, 24 Apr 2026 10:25:04 -0400 - 18 days ago

Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today

2026-04-24T12:16:55.000Z - 18 days ago

Scinai Immunotherapeutics announces $2.61M private placement

Fri, 24 Apr 2026 08:00:00 -0400 - 18 days ago

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

2026-04-06T11:17:23.000Z - 5 weeks ago

Scinai Immunotherapeutics completes strategic reorganization

2026-04-06T11:10:47.000Z - 5 weeks ago

Scinai Immunotherapeutics targets $5M in CDMO revenue in 2026

Mon, 06 Apr 2026 07:00:00 -0400 - 5 weeks ago

Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities

Wed, 01 Apr 2026 07:35:00 -0400 - 6 weeks ago

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

2026-03-19T12:08:05.000Z - 7 weeks ago

Scinai Immunotherapeutics highlights expanded CDMO platform

Mar 19, 2026, 7:50 AM EDT - 7 weeks ago

Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

Mar 16, 2026, 4:05 PM EDT - 2 months ago

Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

2026-03-02T14:30:59.000Z - 2 months ago

Scinai Immunotherapeutics signs second amendment to PinCell option agreement

Mar 2, 2026, 9:20 AM EST - 2 months ago

Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

Feb 25, 2026, 8:11 AM EST - 2 months ago

Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform

Feb 17, 2026, 7:00 AM EST - 3 months ago

Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm

Jan 7, 2026, 7:00 AM EST - 4 months ago

Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL

Dec 2, 2025, 8:50 AM EST - 5 months ago

Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances

2025-10-06T11:40:52.000Z - 7 months ago

Scinai Immunotherapeutics awarded grant from Israel Innovation Authority

Oct 6, 2025, 7:30 AM EDT - 7 months ago

Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities

Sep 2, 2025, 7:30 AM EDT - 9 months ago

Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

2025-07-29T11:31:12.000Z - 10 months ago

Scinai Immunotherapeutics’ PC111 featured in peer-reviewed publication

Jul 29, 2025, 7:15 AM EDT - 10 months ago

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

Jun 12, 2025, 8:00 AM EDT - 11 months ago

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

Jun 5, 2025, 9:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

May 30, 2025, 7:00 AM EDT - 1 year ago

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

May 7, 2025, 4:01 PM EDT - 1 year ago

Scinai Announces Annual Financial Results for 2024

May 1, 2025, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

Mar 27, 2025, 9:25 AM EDT - 1 year ago

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

2025-03-05T12:37:36.000Z - 1 year ago

Scinai Immunotherapeutics announces $10M standby equity purchase agreement

Mar 5, 2025, 7:30 AM EST - 1 year ago

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

2025-03-04T22:30:58.000Z - 1 year ago

Scinai Immunotherapeutics files to sell 3.02M ADS for holders

Jan 6, 2025, 7:31 AM EST - 1 year ago

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Dec 16, 2024, 9:25 AM EST - 1 year ago

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Dec 5, 2024, 8:25 AM EST - 1 year ago

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

Nov 27, 2024, 8:00 AM EST - 1 year ago

Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

Nov 22, 2024, 7:15 AM EST - 1 year ago

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Oct 31, 2024, 6:59 AM EDT - 1 year ago

Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

Sep 9, 2024, 11:12 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.

2024-08-29T10:35:55.000Z - 1 year ago

Scinai Immunotherapeutics regains compliance with Nasdaq

Aug 29, 2024, 6:31 AM EDT - 1 year ago

Scinai Regains Full Compliance with Nasdaq Listing Requirements

Aug 21, 2024, 8:45 AM EDT - 1 year ago

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

Aug 20, 2024, 9:30 AM EDT - 1 year ago

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

2024-07-23T11:13:35.000Z - 1 year ago

Scinai Immunotherapeutics’ IL-17 nanoAb receives positive regulatory feedback

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

Jul 15, 2024, 12:31 PM EDT - 1 year ago

Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results

2024-07-15T11:10:01.000Z - 1 year ago

Scinai Immunotherapeutics’ psoriasis candidate shows efficacy in study

Jul 15, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model

2024-07-08T12:18:12.000Z - 2 years ago

Scinai Immunotherapeutics receives updated LOI from EIB

Jul 8, 2024, 8:14 AM EDT - 2 years ago

Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity

Jul 3, 2024, 9:32 AM EDT - 2 years ago

Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

2024-07-02T12:31:36.000Z - 2 years ago

Scinai Immunotherapeutics reports Q1 EPS ($0.001c) vs ($0.003) last year

Jul 2, 2024, 8:12 AM EDT - 2 years ago

Scinai Publishes Q1 2024 Financial Results and Provides Business Update

Jun 13, 2024, 7:00 AM EDT - 2 years ago

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.

2024-06-07T11:02:39.000Z - 2 years ago

Scinai Immunotherapeutics regains Nasdaq compliance

Jun 7, 2024, 7:00 AM EDT - 2 years ago

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement

May 24, 2024, 4:01 PM EDT - 2 years ago

Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance

May 15, 2024, 4:01 PM EDT - 2 years ago

Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update

May 6, 2024, 9:21 AM EDT - 2 years ago

Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal

Apr 10, 2024, 7:00 AM EDT - 2 years ago

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG

Apr 8, 2024, 7:00 AM EDT - 2 years ago

Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Scinai leadership to attend BIO-Europe Spring 2024

Feb 29, 2024, 8:45 AM EST - 2 years ago

Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024

Feb 13, 2024, 7:00 AM EST - 2 years ago

Scinai Welcomes Liat Halpert as Head of Business Development and Sales

focafoca99 May. 12 at 9:53 PM

$SCNI scheduled its annual shareholders meeting for June 16, 2026.

0 · Reply

CrumbEater May. 8 at 7:46 PM

$SCNI https://www.stocktitan.net/sec-filings/SCNI/6-k-scinai-immunotherapeutics-ltd-current-report-foreign-issuer-a6b6d38f512a.html

0 · Reply

focafoca99 May. 8 at 11:40 AM

$SCNI declares it completed the acquisition of Recipharm Israel and filed audited and pro forma financial statements of the new subsidiary.

0 · Reply

SuperGreenToday Apr. 30 at 8:45 PM

$SCNI

0 · Reply

Richard_Roma Apr. 29 at 1:37 PM

$SCNI of course another placement to dilute shateholders and provide a comfortable living to execs for non-performance.

0 · Reply

Bulltrader988 Apr. 28 at 6:55 PM

0 · Reply

NewbieStar Apr. 28 at 2:13 AM

$SCNI just got in. Looking at exiting at $5

1 · Reply

Joby099 Apr. 27 at 9:24 PM

$SCNI

0 · Reply

Richard_Roma Apr. 27 at 8:40 PM

$SCNI are you not entertained? This flaming dumpster will probably be up for another placement soon, as execs need to maintain their higher standard of living.

0 · Reply

rbobby25 Apr. 27 at 3:28 PM

$SCNI - just jumped into this stock and bought 5000 shares to start. See how today/this week rolls. Looks promising for a bit of a lift off upwards.

1 · Reply

TeamBullish Apr. 27 at 1:16 PM

I’ll be using the first 30 minutes after the open strictly for analysis. There’s a lot of power in that, especially on a Monday with new movers developing. Let the price action show its hand before committing. Prioritize understanding the trend and structure first, then act with intent. I’ll provide updates as things take shape. $USEG $YAAS $ONCO $SCNI $ATOM.X

2 · Reply

Joby099 Apr. 27 at 9:48 AM

$SCNI

1 · Reply

luminouslumens Apr. 27 at 8:13 AM

$SCNI

0 · Reply

morewski Apr. 27 at 7:34 AM

$SCNI It should go to 0.30—it dropped too much after the market closed; it should have held at 0.75 to be bullish

1 · Reply

DavidScott Apr. 27 at 3:02 AM

On watch tomorrow (momentum) // Part 1 🔥📈📚 $SCNI $LIDR $GMEX $POET $ENVB

0 · Reply

Joby099 Apr. 27 at 1:00 AM

$SCNI

0 · Reply

whiskeyhorchata Apr. 27 at 12:31 AM

$SCNI anyone know if the company that had the new shares and warrants could sell the warrants right away?

0 · Reply

Joby099 Apr. 26 at 9:09 PM

$SCNI Everything is clean and easy to follow, no confusion at all https://www.youtube.com/watch?v=-IFh6pnSMsY

0 · Reply

DeepBlueTitan Apr. 26 at 7:58 PM

$SCNI 1$+

0 · Reply

Market Cap	1.81M
Revenue (ttm)	1.31M
Net Income (ttm)	-8.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-634.35%
Debt to Equity Ratio	0.04

Volume	78,700
Avg Vol	4,166,330
Day's Range	N/A - N/A
Shares Out	3.54M
Stochastic %K	9%
Beta	2.19
Analysts	Strong Buy
Price Target	$8.00